Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Health systems and care delivery

Topic: Risk, prevention and care in population studies

Plain-language summary

Lenore Ackerman *Correspondence: David Geffen School of Medicine, 10833 Le Conte Ave, Box 951738, Los Angeles, CA 90095-1738 telephone: 310-794-0206; E-mail Address: [email protected] https://orcid.org/0000-0003-4192-7649 Department of Urology and Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California View All Author Informationhttps://doi.org/10.1097/JU.0000000000003430AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Overactive bladder, including symptoms of increased urinary frequency, urgency, and incontinence, is more prevalent than diabetes, affecting 1 in 6 adults in the United States.1,2 Occurring more commonly among women and older adults, untreated overactive bladder is associated with reduced quality of life, increased incidence of depression and anxiety, increased risk of experiencing falls/fractures, and increased institutionalization. The American Urological Association treatment guidelines for overactive bladder recommend pharmacological treatment with anticholinergics or β3-adrenergic receptor agonists in combination with behavioral therapy as first-line treatment or pharmacological treatment alone as second-line treatment.1 Anticholinergic medications, which have been used to treat overactive bladder for decades, may be effective for some patients but have long been recognized to result in bothersome and persistence-limiting side effects such as constipation and dry mouth. While medication substitutions require provider approval, substitutions can result in anticholinergics being dispensed to patients despite the physician's initial intent to prescribe a different treatment class because anticholinergics may have been inappropriate due to age or potential for cognitive dysfunction or falls. While generally viewed as a benign side effect, constipation alone can impart a significant burden on the health care system, with over 3.7 million office and immediate care visits each year centering on the evaluation and management of constipation (including constipation unrelated to anticholinergic use).6 In addition, constipation may impair productivity, increase psychological distress, and degrade overall quality of life. Evidence from a systematic literature review and meta-analysis supports a heightened risk of Alzheimer disease, incident

What this study adds

Evidence grade: High

This is a pooled review. This review discusses treatment guidelines for overactive bladder, a condition more common than diabetes that is linked to falls, fractures, depression and institutionalization. It does not report any findings about treating, curing or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ackerman, A. L. (2023). Penny-wise but Pound-foolish: The Hidden Costs of Step Therapy for Overactive Bladder. The Journal of Urology. https://doi.org/10.1097/ju.0000000000003430

Vancouver

Ackerman AL. Penny-wise but Pound-foolish: The Hidden Costs of Step Therapy for Overactive Bladder. The Journal of Urology. 2023. doi:10.1097/ju.0000000000003430. PMID: 36950931.

BibTeX

@article{ackerman2023-36950931,
  author  = {Ackerman, A. Lenore},
  title   = {{Penny-wise but Pound-foolish: The Hidden Costs of Step Therapy for Overactive Bladder}},
  journal = {The Journal of Urology},
  year    = {2023},
  doi     = {10.1097/ju.0000000000003430},
  pmid    = {36950931},
  url     = {https://doi.org/10.1097/ju.0000000000003430}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review discusses treatment guidelines for overactive bladder, a condition more common than diabetes that is linked to falls, fractures, depression and institutionalization. It does not report any findings about treating, curing or preventing Alzheimer's disease.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 53 of 100.53 of 100 points earned47 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of Urology)
Journal's citation record 3 / 4 The Journal of Urology: journal h-index 373 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 2 / 7 Cited 8 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.6 citations a year over 5 year(s) since 2023
Impact for its field and year 2 / 6 Cited 2.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author A. Lenore Ackerman: h-index 11 (OpenAlex, whole career)
Institution's track record 2 / 3 University of California, Los Angeles: institution h-index 1,923 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 36950931)
Free to read 2 / 2 Free to read
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Health systems and care delivery from nearby years

Also in Health systems and care delivery

172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →